

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Charles Rudin named cancer center director at MSK
- Pam Bondi diagnosed with thyroid cancer
- As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule














